Suppression of miR-106a-5p expression inhibits tumorigenesis via increasing CELF-2 expression in spinal cord glioma

HAO XU*, FEI WANG* and LIN WANG

Department of Neurosurgery, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui 230000, P.R. China

Received November 14, 2020; Accepted May 13, 2021

DOI: 10.3892/ol.2021.12888

Abstract. Spinal cord glioma is a tumor characterized by high recurrence and mortality rates, and its treatment remains a major challenge. It has been reported that abnormal expression of microRNAs (miRNAs/miRs) is associated with tumor progression. Therefore, the current study aimed to identify novel miRNAs associated with spinal cord glioma. Herein, the expression levels of several miRNAs were determined in human spinal cord glioma and adjacent non-cancerous tissues by reverse transcription-quantitative (RT-qPCR). The results revealed that miR-106a-5p expression was markedly upregulated in spinal cord glioma tissues compared with in non-cancerous tissues. Furthermore, the biological effects of miR-106a-5p on spinal cord glioma cells were evaluated by MTT, Transwell and flow cytometric assays. In 0231SCG cells transfected with miR-106a-5p inhibitor, cell proliferation, migration and invasion were attenuated, whereas apoptosis was enhanced. A search of the TargetScan database revealed that miR-106a-5p directly targeted CUGBP Elav-like family member 2 (CELF-2). Western blot and RT-qPCR experiments further confirmed the association between miR-106a-5p and CELF-2 expression in spinal cord glioma tissues. The current results demonstrated that CELF-2 was a direct target of miR-106a-5p, and that the expression levels of CELF-2 were negatively associated with those of miR-106a-5p. In addition, overexpression of CELF-2 in spinal cord glioma cells reversed the tumor-promoting effects of miR-106a-5p both in vitro and in vivo. Overall, the aforementioned findings indicated that miR-106a-5p, which was highly expressed in spinal cord glioma tissues, may affect the proliferation, migration, invasion and apoptosis of spinal cord glioma cells via targeting CELF-2, thus indicating a potential approach to the future clinical management of spinal cord glioma.

Introduction

Spinal cord glioma accounts for >80% of all spinal intramedullary tumors (1,2). Due to the high recurrence and poor survival rates of patients with spinal cord glioma, its treatment is considered challenging (3,4). Studies have suggested that the abnormal invasion, proliferation, migration and apoptosis of spinal cord glioma cells are the main obstacles to improving prognosis (5,6). Although progress has been made in conventional treatments, their therapeutic effects are not satisfactory (7). Therefore, the identification of novel therapeutic targets and the development of mechanism-based approaches are urgently required.

MicroRNAs (miRNAs/miRs) are endogenous non-coding single-stranded RNAs 20-25 nucleotides in length, which have regulatory functions and are present in the genomes of most eukaryotes (8). According to the principle of complementary base pairing, the 3'-untranslated region (3'-UTR) of a target mRNA is identified by a miRNA, and the silencing complex is guided to degrade or inhibit the translation of the target mRNA. Certain miRNA precursors can form two stably expressed mature miRNA, with the difference that ‘-3p’ or ‘-5p’ is added to the end of the name depending on where it advances (9). Recently, increasing evidence has demonstrated that miRNAs serve an important role in specific cellular processes, such as cell differentiation, morphology and tumor formation (10,11).

During tumorigenesis and tumor development, miRNAs may act as oncogenes or tumor suppressor genes, and are involved in the regulation of tumor-associated genes (12). Studies have suggested that miR-21 (13), miR-10b (14), miR-95-3p (15), miR-106a-5p (16), miR-615-3p (17) and miR-155 (18) are important tumor growth factors. The different expression profiles between glioma and non-cancerous tissues may partially elucidate the roles of different miRNAs in tumorigenesis, and may be therefore used to predict new therapeutic targets (18).

In the present study, the expression levels of miR-21, miR-10b, miR-95-3p, miR-106a-5p, miR-615-3p and miR-155 were compared between spinal cord glioma and non-cancerous spinal cord tissues by reverse transcription-quantitative PCR (RT-qPCR). Since miR-106a-5p was highly expressed in
spinal cord glioma tissues compared with in non-cancerous tissues, it was hypothesized that miR-106a-5p may serve as a gene mediating the growth of spinal cord glioma. To verify this hypothesis, the effects of miR-106a-5p on cell proliferation, migration, invasion and apoptosis of spinal cord glioma cells were evaluated. Furthermore, the results revealed an inverse association between CUGBP Elav-like family member 2 (CELF-2) and miR-106a-5p expression in human spinal cord glioma samples. Therefore, the effect of CELF-2 overexpression on the biological activity of spinal cord glioma cells was evaluated in vitro and in vivo.

Materials and methods

Cell culture and transfection. Human spinal cord glioma and non-cancerous spinal cord tissues (normal adjacent tissues) were collected from the Department of Neurosurgery of The First Affiliated Hospital of University of Science and Technology of China (Hefei, China). All 21 patients (admitted between February 2017 and July 2018; age range, 16-60 years; median age, 46 years) provided written informed consent prior to enrolment. The present study was approved by the Institutional Review Board of The First Affiliated Hospital of University of Science and Technology of China. Patient 02-13 was randomly selected for the isolation of spinal cord glioma cells (0213SCG cells). Fresh human spinal cord glioma tissue was cut into 1-mm³ pieces and washed 2-3 times with PBS supplemented with 1% penicillin/streptomycin solution (Gibco; Thermo Fisher Scientific, Inc.). PBS was removed and 0.25% trypsin was added to digest the tumor tissue mass at 37°C in a water bath for 30 min. The digested cell fluid was passed through a 100-mesh steel strainer to prepare a tumor cell suspension, which was in turn transferred to a centrifuge tube followed by centrifugation at 241 x g for 3 min at room temperature. Subsequently, the cells were resuspended in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) containing 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin solution, and were cultured at 37°C in a 5% CO₂ incubator. For tracking transplanted spinal cord glioma cells in vivo, 0213SCG cells were transfected with a self-inactivating lentiviral vector carrying an ubiquitin promoter driving the expression of firefly luciferase and enhanced green fluorescence protein (Fluc-eGFP) at a density of 8x10⁴ cells/well. To detect the effects of miR-106a-5p inhibitors on cell proliferation, 0213SCG cells were transfected with miR-106a-5p inhibitors or NC inhibitors, as aforementioned. Cell proliferation was then determined after 24 and 48 h by MTT assay using dimethyl sulfoxide as the solvent according to the manufacturer's instructions (Sigma-Aldrich; Merck KGaA). Furthermore, to evaluate the effect of CELF-2 overexpression on miR-106a-5p on 0213SCG cells and 0213SCG cells overexpressing CELF-2 were seeded into 96-well plates at a density of 8x10³ cells/well. To detect the effects of miR-106a-5p inhibitors on cell proliferation, 0213SCG cells were transfected with miR-106a-5p inhibitors or NC inhibitors, as aforementioned.

Western blot analysis. For CELF-2 protein expression analysis, the cells or tissues were lysed on ice with radio-immunoprecipitation assay buffer supplemented with a protease inhibitor cocktail (Sigma-Aldrich; Merck KGaA). The tumor tissues were specifically lysed for 30 min. BCA reagent (Thermo Fisher Scientific, Inc.) was used to quantify the protein concentration. Total cell or tissue proteins (50 µg/lane) were separated by 10% SDS-PAGE and transferred onto PVDF membranes (EMD Millipore).
Following blocking with 5% skimmed dry milk in Tris-buffer containing 0.05%-Tween-20 (TBST) for 2 h at room temperature, the membranes were incubated with primary antibodies at 4°C overnight. The membranes were washed thrice with TBST for 5 min each time, and were then incubated with HRP-conjugated secondary antibodies (1:10,000; cat. no. VA001; Vicsmed Biotech Co., Ltd.) at room temperature for 2 h. Following washing with TBST for three times, the blots were visualized using the SuperSignal West Dura Extended Duration Substrate (Thermo Fisher Scientific, Inc.). The primary antibodies used were against GADPH (1:1,000; cat. no. ab9485; Abcam) and CELF-2 (1:400; cat. no. PA1-4130; Thermo Fisher Scientific, Inc.). GADPH served as the internal control. The grey levels of western blot analysis were measured and quantified using ImageJ software (version ImageJ2; National Institutes of Health).

Tumor model and bioluminescence imaging (BLI). Male nu/nu Nude mice (age, 6-8 weeks; weight 22 g; n=40) were purchased from the Beijing Weitonglihua Experimental Animal Co., Ltd., and were housed under standard laboratory conditions (temperature, 20-26°C; relative humidity, 40-60%; noise, <60 dB; ventilation degree, 10-20 times/h; light/dark cycle, 12/12 h; adequate food and drinking water.). All experimental procedures were conducted in accordance with the institutional guidelines of the University of Science and Technology of China for The Care and Use of Laboratory Animals and conformed to the National Institutes of Health Guide for Care and Use of Laboratory Animals [approval no. 2019-N (A)-011]. Mice received subcutaneous injection of 100 µl of the cell suspension containing 1x10^6 0213SCG cells (Fluc-eGFP) into the right forelimb armpit. In addition, the following humane endpoints were established in the present study: i) The tumor burden should not exceed 5% of the normal body weight of the mouse; ii) the tumor should not grow to a position that seriously affects the normal function of the mouse, and the growth of the tumor should not cause pain in the mouse; iii) the weight loss of mice should not exceed 20% of the body weight of normal mice; iv) there should be no ulcers or infections at the growth point of the tumor; and v) mice should not exhibit self-harming behavior. Animals were monitored every 3 days to evaluate tumor progression. To monitor tumor development, BLI was applied using the Imaging System IVIS Lumina (Xenogen Corp.). To detect Fluc expression at days 1, 4, 7, 10, 17 and 20, mice were intraperitoneally injected with D-luciferin at a dose of 100 mg/kg body weight; J&K Scientific Ltd.). The dose of isoflurane used to intraperitoneally inject D-luciferin (150 mg/kg body weight; J&K Scientific Ltd.) at 4°C for 30 min. A total of 1x10^4 0213SCG cells transfected with miR-106a-5p inhibitors or NC inhibitors were seeded into the inserts and cultured with serum-free RPMI-1640 medium, and RPMI-1640 medium containing 10% FBS was added to the lower chambers. Cell migration and invasion were also determined in CELF-2 overexpressing 0213SCG cells. Flow cytometry was utilized to determine the apoptotic rate of 0213SCG cells transfected with miR-106a-5p inhibitors and respective NC. Furthermore, the mean fluorescence of the cells was measured using a rabbit anti-human CELF-2 antibody (1:400; cat. no. PA1-4130; Thermo Fisher Scientific, Inc.). In addition, apoptosis and proliferation in tumor tissues were detected using the cleaved capase-3 (cat. no. ab49822) and Ki67 (cat. no. ab15580) antibodies (both 1:400; Abcam), respectively. To monitor tumor development, BLI was applied using the Imaging System IVIS Lumina (Xenogen Corp.). To detect Fluc expression at days 1, 4, 7, 10, 17 and 20, mice were intraperitoneally injected with D-luciferin (150 mg/kg body weight; J&K Scientific Ltd.). The dose of iso-flurane used to intraperitoneally inject D-luciferin at 4°C for 30 min. A total of 1x10^4 0213SCG cells transfected with miR-106a-5p inhibitors or NC inhibitors were seeded into the inserts and cultured with serum-free RPMI-1640 medium, and RPMI-1640 medium containing 10% FBS was added to the lower chambers. Cell migration and invasion were also determined in CELF-2 overexpressing 0213SCG cells. Following culture for 24 h at 37°C, non-migrating or non-invading cells on the upper side of the filter were removed with a cotton swab. The migrated or invasive cells were stained with crystal violet for 15 min at room temperature and counted at 6 randomly selected fields at x20 magnification under an optical microscope (Carl Zeiss AG).
and oligo(dT) primers of an RT kit (cat. no. AE101-02; TransGen Biotech Co., Ltd.) following the manufacturer’s protocol. Real-time PCR was performed with SYBR-Green on the Bio-Rad Real-Time PCR System (Bio-Rad Laboratories, Inc.). The expression levels of miR-21, miR-10b, miR-155, miR-106a-5p, miR-95-3p, miR-615-3p and CELF-2 were quantified using SYBR-Green qPCR (TransGen Biotech Co., Ltd.). The 2^−ΔΔCq method (20) was used to analyze the relative mRNA fold-changes. Primers are listed in Table SI. In the experiments, GAPDH was used as an internal control for mRNA, and U6 was used as an internal control for miRNA. The thermocycling conditions were as follows: 94˚C for 5 min, followed by 40 cycles at 94˚C for 30 sec, 60˚C for 25 sec and 72˚C for 25 sec.

Statistical analysis. All statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, Inc.). All data were expressed as the mean ± SEM. Mixed two-way ANOVA was used to evaluate tumor growth at different time points in the control and CELF-2 OE groups, and the Bonferroni test was used as the post-hoc test. Paired Student's t-test was used to analyze the differences between cancerous and non-cancerous tissues. The correlation between Fluc fluorescence intensity and cell number was analyzed by unary linear regression in 0213SCG cells transfected with Fluc-eGFP. For the other datasets, statistically significant differences between two or multiple groups were assessed by unpaired Student's t-test or one-way ANOVA with Tukey's post-hoc test, respectively. P<0.05 was considered to indicate a statistically significant difference.

Results

miR-106a-5p expression is upregulated in spinal cord glioma tissues. It has been reported that miR-21, miR-10b, miR-95-3p, miR-106a-5p, miR-615-3p and miR-155 are significant regulators of tumor growth (13-18). Therefore, the expression levels of the aforementioned six miRNAs were determined in spinal cord glioma and non-cancerous tissues (normal adjacent tissues) from patient 02-13. The results demonstrated that only miR-106a-5p and miR-95-3p expression was upregulated in spinal cord glioma tissues compared with in non-cancerous tissues (Fig. 1). Compared with normal tissues, miR-106a-5p expression was markedly upregulated in spinal glioma tissue samples compared with in normal tissues in all patients (Fig. S1A and B). Therefore, the current findings suggested that miR-615-3p may play a carcinogenic role in spinal cord glioma.

Tumor-promoting effect of miR-106a-5p. Emerging evidence has suggested that miR-106a-5p expression is upregulated or downregulated in different tumor tissues (21-25). However, to the best of our knowledge, the effect of miR-106a-5p in
spinal cord glioma has not been previously investigated. To explore the effect of miR-106a-5p on 0213SCG cells isolated from patients with 02-13 spinal cord glioma, cells were transiently transfected with miR-106a-5p inhibitors or mimics or the corresponding NCs (inCON or miCON, respectively). The expression levels of miR-106a-5p in transiently transfected 0213SCG cells were significantly suppressed by the miR-106a-5p inhibitor. (D) Representative photographs of Transwell invasion assay of 0213SCG cells treated with PBS, inCON and miR-106a-5p inhibitor. Scale bar: 100 µm. (E) Quantitative analysis results revealed that the invasion of 0213SCG cells was significantly suppressed by the miR-106a-5p inhibitor. (F) Flow cytometry was used to analyze the apoptosis of 0213SCG cells treated with PBS, inCON and miR-106a-5p inhibitor. (G) Quantitative analysis results revealed that miR-106a-5p inhibitors significantly increased the apoptosis of 0213SCG cells. Data are expressed as the mean ± SEM. *P<0.05. All experiments were performed in triplicate. 0213SCG cells, spinal cord glioma cells isolated from patient 0213; inCON, miR-106a-5p inhibitor negative control; miR, microRNA; OD, optical density.

The results revealed that 0213SCG cells transfected with miR-106a-5p inhibitors exhibited a significantly increased apoptosis rate compared with those treated with inCON and PBS (Fig. 2F and G). However, compared with the cells in the miCON and PBS groups, the apoptosis rate was not markedly changed in 0213SCG cells transfected with miR-106a-5p mimics (Fig. S2D). Overall, the aforementioned results suggested that miR-95-3p inhibition affected the proliferation, migration, invasion and apoptosis of 0213SCG cells.

miR-106a-5p suppresses CELF-2 expression in spinal cord glioma cells. Previous studies have revealed that CELF-2 is a tumor suppressor and is inversely associated with cancer cell migration, invasion, proliferation and apoptosis (26-28). However, the effect of CELF-2 in spinal cord glioma has not been previously reported. To evaluate whether miR-106a-5p could regulate the occurrence of spinal cord glioma via regulating CELF-2, the TargetScan database was utilized to predict the potential target mRNAs of miR-106a-5p. Among all the predicted target-mRNAs, the analysis revealed that CELF-2 could be a putative target gene of miR-106a-5p, since its potential binding site was identified (Figs. 3A and S3). To verify that miR-106a-5p could directly target CELF-2, total RNA and proteins were isolated from transplanted tumor cells.
XU et al: miR-106a-5p SUPPRESSION INHIBITS TUMORIGENESIS OF SPINAL CORD GLIOMA

miR-106a-5p suppression inhibits tumorogenesis of spinal cord glioma. SUPPRESSION INHIBITS TUMORIGENESIS OF SPINAL CORD GLIOMA

To determine whether miR-106a-5p promoted the development of spinal cord gliomas via targeting CELF-2, a 0213SCG cell line transiently overexpressing CELF-2 was established. CELF-2 overexpression was verified by western blot analysis (Fig. 3E and F). Subsequently, to reveal whether CELF-2 overexpression could affect the proliferation of 0213SCG cells, MTT assay was performed. The results indicated that, compared with control 0213SCG cells, the proliferation of CELF-2-overexpressing 0213SCG cells was significantly decreased (Fig. 3G). In addition, CELF-2 overexpression markedly decreased the migration and invasion of 0213SCG cells (Fig. 3H and I). The current findings suggested that CELF-2 may be a functional downstream target of miR-106a-5p regulating the development of spinal cord glioma.

**Overexpression of CELF-2 exerts tumor-suppressive effects.**

To determine the effect of CELF-2 overexpression on spinal cord glioma growth, Fluc imaging was performed to monitor tumor progression. First, to monitor transplanted cells in vivo, an imaging assay was developed using corresponding reporter genes. Transduction of 0213SCG cells was performed with double fusion (DF) (Fig. 4A). Fluorescence microscopy images...
revealed that eGFP was robustly expressed in 0213SCG cells (Fig. 4B). In addition, a strong association between Fluc activity and 0213SCG cell number was revealed, suggesting that tumor growth may be assessed in vivo by analyzing firefly signal intensity (Fig. 4C and D). A spinal cord glioma model was established in nu/nu nude mice by subcutaneously injecting 1x10^5 0213SCG cells or CELF-2-overexpressing 0213SCG cells labeled with DF reporter gene into the right forelimb armpit. BLI of Fluc was performed to monitor the development of tumors. Fluc signals were detected at different time points (days 1, 4, 7, 10, 17 and 20). The results indicated that the tumor growth was significantly attenuated in the CELF-2 overexpression group compared with in the control group (Fig. 4E and F). Compared with the control group,

Figure 4. Overexpression of CELF-2 inhibits tumor progression in vivo. (A) Schematic for the double fusion reporter gene construct Fluc-eGFP driven by the ubiquitin promoter. (B) Fluorescence imaging of eGFP in 0213SCG cells transfected with Fluc-eGFP. Scale bar, 100 µm. (C) Representative bioluminescence images. (D) In vitro imaging analysis of stably transfected 0213SCG cells revealed a strong correlation between cell numbers and Fluc reporter gene activity. (E) Real-time monitoring of tumor progression with Fluc imaging. (F) Quantitative analysis of Fluc signal. (G) Representative images of CELF-2 (red) expression on day 20. Quantitative analysis revealed that CELF-2 protein was highly expressed in the tumors of the CELF-2 overexpression group. Representative images of (H) Cleaved-Caspase-3 and (I) Ki67 protein staining (red) on day 20 and quantitative analysis of apoptotic or proliferating cells. Scale bar, 50 µm. Data are expressed as the mean ± SEM. *P<0.05 vs. Control. All experiments were performed in triplicate. CELF-2, CUGBP Elav-like family member 2; OE, overexpression; eGFP, enhanced green fluorescent protein; Fluc, firefly luciferase.
immunofluorescence staining revealed that CELF-2 was highly expressed in the tumors of the CELF-2 overexpression groups (Fig. 4G). TUNEL staining assay demonstrated a high number of apoptotic CELF-2-overexpressing 0213SCG cells on day 20 (Fig. S4A and B). Furthermore, the results of cleaved-caspase-3 and Ki67 staining indicated that apoptosis was enhanced, whereas cell proliferation was inhibited in the CELF-2-overexpressing 0213SCG cell group (Fig. 4H and I). The aforementioned results suggested that CELF-2 may partially alleviate spinal cord glioma growth.

Discussion

Several miRNAs have been identified as regulators of multiple biological processes in cancer (29). Herein, the differentially expressed miRNAs (miR-106a-5p, miR-21, miR-10b, miR-155, miR-95-3p and miR-615-3p) were screened in patients with spinal cord glioma by RT-qPCR. The analysis revealed that miR-106a-5p expression was upregulated in spinal cord glioma tissues. Previously studies have suggested that miR-106a-5p may both promote and inhibit tumor progression (21-25). Currently, the effect of miR-106a-5p in spinal cord glioma has not been reported. Therefore, the present study aimed to perform functional experiments on multiple aspects of spinal cord glioma development, including proliferation, migration, invasion and apoptosis. To establish an experimental group, 0213SCG cells isolated from spinal cord glioma tissues were transfected with miR-106a-5p inhibitor to knock down miR-106a-5p expression. MTT assay revealed that transfection with miR-106a-5p inhibitor alleviated the proliferation of 0213SCG cells. Since tumor cell migration and invasion are key factors in tumor metastasis (30), Transwell assays were performed to investigate the effect of miR-106a-5p on these processes. As expected, the number of migrating and invading miR-106a-5p inhibitor-transfected cells was decreased compared with the other groups. Apoptosis analysis revealed that the apoptosis rate was significantly enhanced in the miR-106a-5p inhibitor group.

Subsequently, the current study aimed to uncover the mechanism of miR-106a-5p in spinal cord glioma. The TargetScan online database was used to predict the targets of miR-106a-5p. Among all predicted target mRNAs, CELF-2 was selected as a putative target of miR-106a-5p, since a potential binding site for miR-106a-5p was predicted in the 3′-UTR of CELF-2. Emerging evidence has suggested that CELF-2 acts as a tumor suppressor (26-28). Online miRNA target prediction tools have predicted several potential miRNA targets (www.targetscan.org). However, the regulation of CELF-2 by miRNAs has been poorly studied. It has been reported that miR-95-3p targets CELF-2 in glioma (31). Therefore, miR-95-3p downregulation may inhibit cell proliferation and invasion and promote apoptosis (31). Therefore, the present study hypothesized that CELF-2 may also be associated with the occurrence of spinal cord glioma. RT-qPCR and western blot analysis revealed a negative association between CELF-2 and miR-106a-5p expression in spinal cord glioma tissues. Additionally, CELF-2 may be directly targeted by miR-106a-5p.

A previous study has demonstrated that CELF-2 hypermethylation is associated with shorter overall survival of patients with breast cancer in the clinical setting, while CELF-2 restoration exerted an inhibitory effect on breast cancer growth (32). Therefore, it has been suggested that the epigenetic loss of CELF-2 may enhance breast cancer growth and may be associated with worse outcomes in patients with breast cancer (32). Therefore, the current study hypothesized that CELF-2 may be a potential novel therapeutic target for cancer. Herein, CELF-2 overexpression was shown to attenuate the proliferation, migration and invasion of spinal cord glioma cells in vitro. Furthermore, when CELF-2-overexpressing spinal cord glioma cells were transplanted into mice, BLI revealed that the proliferation of spinal cord glioma cells was alleviated. Additionally, an increased number of apoptotic cells was observed in CELF-2-overexpressing spinal cord glioma tissues. The current findings further supported that CELF-2 may affect the proliferation of spinal cord glioma cells via promoting apoptosis. However, the specific molecular mechanisms underlying the effects of CELF-2 should be further investigated.

Overall, the present study demonstrated that miR-106a-5p expression was abnormally upregulated in spinal cord glioma samples, while miR-106a-5p downregulation inhibited the proliferation, migration and invasion, and promoted apoptosis of spinal cord glioma cells via upregulating CELF-2. In addition, the expression levels of miR-106a-5p and CELF-2 may be associated with the clinical characteristics of patients, so there may be potential applications in clinical practice, although this requires further investigation. In summary, it is important to first find the common characteristics of heterogeneous tumors, and secondly, verify this common point in other samples one by one. Through the systematic analysis of multiple samples, the goal of discovering universal phenomena may be finally achieved.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Fundamental Research Funds for the Central Universities (grant no. WK9110000126).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

HX and FW performed the experiments and data analysis. HX and LW conceived and designed the study. HX and FW performed the experiments and data analysis. HX and LW conceived and designed the study.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of The First Affiliated Hospital of University of Science and
Technology of China (Hefei, China). Written informed consent was obtained from all patients. The legal guardians of minors or subjects restricted from participating in this study provided informed consent on their behalf. All animal experimental procedures were conducted in accordance with the institutional guidelines of the University of Science and Technology of China for The Care and Use of Laboratory Animals and conformed to the National Institutes of Health Guide for Care and Use of Laboratory Animals [approval no. 2019-N (A)-011].

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.